ClinicalTrials.gg
RecruitingNCT07797478Updated Nov 17, 2026

A Study of RO7890597 in Healthy Adult Volunteers

A Phase 1 interventional study of RO7890597 and Placebo in Healthy Volunteers, sponsored by Genentech, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 17, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
139
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will evaluate the safety, pharmacokinetics (PK), and activity of single and multiple doses of RO7890597 compared with placebo in healthy volunteers. The study includes single ascending dose (SAD) stage, multiple ascending dose (MAD) stage, food-effect and proton pump inhibitor (PPI) stages, and a supplemental drug-drug interaction (DDI) stage.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Agreement to adhere to the requirements.
  • of 18 to 30 kilograms per square meter (kg/m²).

Exclusion criteria

Exclusion Criteria:

  • Pregnant, breastfeeding, or intending to become pregnant during the study or required period.
  • Treatment with biologic therapy within 90 days or 5 elimination half-lives, whichever is longer, before study drug initiation.
  • Treatment with investigational non-biologic therapy within 28 days or 5 elimination half-lives, whichever is longer, before study drug initiation.
  • Treatment with medication within 28 days or 5 elimination half-lives, whichever is longer, before study drug initiation.
  • Treatment with any vaccine within 14 days prior to initiation of study drug, or within 28 days for a live or .
  • Poor peripheral venous access.
  • Major surgery within 28 days before study drug initiation or planned major surgery during the study.
  • Current infection or recent infection requiring antibiotics as defined in the protocol.
  • History of within 5 years before screening, except for specified adequately treated cancers.
  • History of drug or food allergy.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
139 participants (estimated)

Study arms

  • Experimental
    RO7890597

    Participants will receive a single or multiple doses of RO7890597 alone, or with rabeprazole or itraconazole.

    Drug: RO7890597 · Drug: Rabeprazole · Drug: Itraconazole

  • Experimental
    Placebo

    Participants will receive single or multiple doses of matching placebo.

    Drug: Placebo

Interventions

  • DrugRO7890597

    Participants will receive RO7890597 as per the schedule described in the protocol.

  • DrugPlacebo

    Participants will receive matching placebo as per the schedule described in the protocol.

  • DrugRabeprazole

    Participants will receive rabeprazole as per the schedule described in the protocol.

  • DrugItraconazole

    Participants will receive itraconazole as per the schedule described in the protocol.

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events (AEs)

    Time frame: Up to approximately 12 weeks

Secondary outcomes

  1. Plasma Concentration of RO7890597

    Time frame: At prespecified timepoints from baseline up to approximately 12 weeks

  2. Plasma Concentration of RO7890597 Under Fasted and Fed Conditions

    Time frame: At prespecified timepoints from baseline up to approximately 12 weeks

  3. Plasma Concentration of RO7890597 Alone and in Combination With Rabeprazole

    Time frame: At prespecified timepoints from baseline up to approximately 12 weeks

07

Study locations

1 of 1 sites recruiting
  • ICON (LPRA) - Lenexa
    Lenexa, Kansas 66219, United States
    Recruiting
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2026
First posted
Sep 1, 2026
StartActual
Aug 28, 2026
Primary completionEst.
Jun 15, 2027
CompletionEst.
Jun 15, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 8, 2027→Jun 15, 2027
Nov 17, 2026
Study completion
Jun 8, 2027→Jun 15, 2027
Nov 17, 2026
Show all 2 updates
  1. Nov 17, 2026
    Primary completion Jun 8, 2027→Jun 15, 2027
    Study completion Jun 8, 2027→Jun 15, 2027
    + 1 other change: verification date
  2. Oct 16, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07797478
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Sep 1, 2026
Start date
Aug 28, 2026
Primary completion
Jun 15, 2027 (estimated)
Completion
Jun 15, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Reference Study ID Number: GA46708 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion